Company intelligence / Profile preview

EmStop

Ownership: Private
Development stage: Clinical

Overview

EmStop has completed the CAPTURE-1 early feasibility clinical trial evaluating its integrated embolic protection system for use during TAVR. The study involved 15 patients at two US sites and demonstrated feasibility and safety of the system to capture and remove thrombus or debris during the procedure. Patients will be monitored for 30 days post-procedure to assess long-term safety outcomes. Results are being prepared for regulatory submission, with further trials planned[2][4][5].

Therapeutic areas: Cardiovascular
Modalities: DeviceEmbolic protection device (medical device)
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on EmStop.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EmStop.

Explore the full profile